Literature DB >> 682528

[Effect of saralasin on plasma renin activity and arginine-vasopressin in patients with angiotensin-dependent hypertension (author's transl)].

I P Arlart, H Wagner, J Rosenthal.   

Abstract

A central stimulatory effect of angiotensin II (AII) on the secretion of arginine-vasopressin (AVP) has been described. The competitive blocker of AII, saralasin (SAR) has been used for diagnostic purposes in angiotensin-dependent hypertension. In addition SAR has a partially agnoistic effect. The aim of the present study was to demonstrate whether AVP-levels can be influenced during SAR-induced renin stimulation. In 9 patients with essential hypertension blood pressure dropped significantly under SAR (10 microgram/kg/min over a 30 min period). Before and after SAR plasma renin activity (PRA) and AVP were measured by RIA, SAR evoked significantly increments of PRA in all patients and of AVP in 6 patients. The increased serum concentrations of AVP following SAR may be explained either by the depressor effect of SAR, its diminished concentration at the central receptor, or a partial AII-agonistic effect.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 682528     DOI: 10.1007/BF01477012

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Release of vasopressin by angiotensin II.

Authors:  L C Keil; J Summy-Long; W B Severs
Journal:  Endocrinology       Date:  1975-04       Impact factor: 4.736

2.  Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man.

Authors:  P L Padfield; J J Morton
Journal:  J Endocrinol       Date:  1977-08       Impact factor: 4.286

3.  Improved method and its clinical application of a radioimmunoassay of arginine vasopressin in human serum.

Authors:  H Wagner; V Maier; H E Franz
Journal:  Horm Metab Res       Date:  1977-05       Impact factor: 2.936

Review 4.  Effects of angiotensin on the central nervous system.

Authors:  W B Severs; A E Daniels-Severs
Journal:  Pharmacol Rev       Date:  1973-09       Impact factor: 25.468

5.  Central action of angiotensin in stimulating ADH release.

Authors:  D Mouw; J P Bonjour; R L Malvin; A Vander
Journal:  Am J Physiol       Date:  1971-01

6.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

7.  Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.

Authors:  D H Streeten; G H Anderson; J M Freiberg; T G Dalakos
Journal:  N Engl J Med       Date:  1975-03-27       Impact factor: 91.245

8.  Angiotensin stimulated AVP-release in humans.

Authors:  E Uhlich; P Weber; J Eigler; U Gröschel-Stewart
Journal:  Klin Wochenschr       Date:  1975-02-15

9.  Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.

Authors:  N K Hollenberg; G H Williams; B Burger; I Ishikawa; D F Adams
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

10.  Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

Authors:  D B Case; J M Wallace; H J Keim; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.